| DB ID | MyCo_1416 |
| Title | Identifying host microRNAs in bronchoalveolar lavage samples from lung transplant recipients infected with Aspergillus |
| Year | 2020 |
| PMID | 32771440 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | LUNG TRANSPLANT RECIPIENTS |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | This study was approved by the Research Ethics Board of University Health Network, University of Toronto. |
| Site of Infection | Lungs |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | miR-4488 |
| Biomarker Full Name | miR-4488 |
| Biomarker Type | Diagnostic |
| Biomolecule | miRNA |
| Geographical Location | Canada |
| Cohort | This study was approved by the Research Ethics Board of University Health Network, University of Toronto. BAL samples were collected from LTRs at University Health Network between January 2012 and October 2016 for clinical purposes (REB 13-7218). Surveillance bronchoscopies are performed at 2 and 6 weeks and 3, 6, 9, 12, and 18 months after lung transplantation. In addition, diagnostic bronchoscopies were performed when infection or rejection was suspected in LTRs. Samples were stored at −80°C until analyzed. The BAL samples –were obtained from: 10 patients with only Aspergillus colonization (ASP group), 7 patient who had Aspergillus colonization and CLAD (ASPCLAD group), 10 patients who developed IA without CLAD (IA group), 9 patients who had CLAD and also developed IA (IACLAD), and 9 control patients (CONTROLS) who did not develop CLAD, IA, nor Aspergillus colonization. The BAL samples from Aspergillus colonization and IA patients only had fungal growth and the samples from control patients has no microbial growth. |
| Cohort No. | 36 Patients and 9 Controls |
| Age Group | None |
| P Value | p<0.01 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | 6 fold |
| Pathway | None |
| Disease Introduction Mechanism | Lung transplantation has become an established mode of treatment for patients with end stage pulmonary disease. As the number of lung transplants continues to grow steadily every year, the two main impediments to survival remain chronic lung allograft dysfunction (CLAD) and non-CMV infections. Among lung transplant recipients (LTRs) surviving 10 years, CLAD is present in 65% of patients, and non-cytomegalovirus (CMV) infections, including Aspergillus infection, account for 16.7% of deaths. Aspergillus spp are the most common cause of fungal infections in LTRs. Aspergillus infection can present as colonization or as invasive disease (invasive aspergillosis, IA). The primary barrier to early diagnosis of Aspergillus infection is the lack of sensitivity of available diagnostic tests. |
| Technique | Bioinformatics analysis |
| Analysis Method | Computational Nanostring nCounter Analysis |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Computational Nanostring nCounter Analysis |
| Up Regulation Down Regulation | Up regulated |
| Sequence Data | None |
| External Link | None |
